Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma

• Published in: Clinical lymphoma & myeloma 2009-12, Vol.9 (6), p.412-416
• Main Authors: Duvic, Madeleine, Olsen, Elise A., Breneman, Debra, Pacheco, Theresa R., Parker, Sareeta, Vonderheid, Eric C., Abuav, Rachel, Ricker, Justin L., Rizvi, Syed, Chen, Cong, Boileau, Kathleen, Gunchenko, Alexandra, Sanz-Rodriguez, Cesar, Geskin, Larisa J.
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic Agents - therapeutic use; Erythroderma; Female; Histone deacetylase inhibitor; Histone Deacetylase Inhibitors - therapeutic use; Humans; Hydroxamic Acids - adverse effects; Hydroxamic Acids - therapeutic use; Lymphoma, T-Cell, Cutaneous - drug therapy; Male; Middle Aged; Mycosis fungoides; Skin Neoplasms - drug therapy; Sézary syndrome
• ISSN: 1557-9190; 1938-0712
• DOI: 10.3816/CLM.2009.n.082

Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after treatment with 2 systemic therapies. A multicenter, open-label phase IIb trial evaluated the activity and safety of vorinostat 400 mg orally daily in patients with ≥ stage IB, persistent, progressive, or treatment-refractory mycosis fungoides or Sézary syndrome CTCL subtypes. We report the safety and tolerability of long-term vorinostat therapy in patients who experienced clinical benefit in the previous phase IIb study. As of December 11, 2008, 6 of 74 patients enrolled in the original study had received vorinostat for ≥ 2 years: median age, 65 years; median number of previous therapies, 2.5; median time from diagnosis to enrollment, 1.8 years. At enrollment into the continuation phase, 5 of the 6 patients had achieved an objective response, and 1 patient had prolonged stable disease. During the follow-up study, the most common drug-related grade 1–4 adverse events (AEs) were diarrhea, nausea, fatigue, and alopecia (6, 5, 4, and 3 patients, respectively). Incidence of grade 3/4 AEs was low: anorexia (n = 1), increased creatinine phosphokinase (n = 1), pulmonary embolism (n = 1), rash (n = 1), and thrombocytopenia (n = 1). Five patients have discontinued the study drug, and 1 patient is continuing therapy. This post hoc subset analysis provides evidence for the long-term safety and clinical benefit of vorinostat in heavily pretreated patients with CTCL, regardless of previous treatment failures.